Sangun Lee

Sangun Lee

Auto-generated profile, based on publicly available information

Sangun Lee

Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SLSangun Lee
Sangun Lee
MGMelanie Ginese
Melanie Ginese
GBGillian Beamer
Gillian Beamer
HDHillary R. Danz
Hillary R. Danz
DGDonald J. Girouard
Donald J. Girouard
STSaul Tzipori
Saul Tzipori
Recent reports highlighting the global significance of cryptosporidiosis among children have renewed efforts to develop control measures. We evaluated the efficacy of bumped kinase inhibitor (BKI) 1369 in the gnotobiotic piglet model of acute diarrhea caused by Cryptosporidium hominis, the species responsible for most human cases. Five day-treatment with BKI 1369 reduced signs of disease early during treatment compared with untreated animals. Piglets treated with BKI 1369 exhibited a significant reduction of oocyst excretion, mucosal colonization by C. hominis, and mucosal lesions, which resulted in considerable symptomatic improvement. BKI 1369 reduced parasite burden and disease severity in the gnotobiotic pig model. Together, these data suggest that the BKI-mediated therapeutic could potentially be an effective treatment against cryptosporidiosis.

27 August 2018 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
SLSangun Lee
Sangun Lee
GBGillian Beamer
Gillian Beamer
STSaul Tzipori
Saul Tzipori
Cryptosporidium spp. are ranked as the second leading pathogens causing life-threatening diarrhea in children under 2 years of age. Although Cryptosporidium hominis causes three quarters of the cases of cryptosporidiosis, studies on C. hominis are limited since natural disease due to C. hominis is host-restricted to humans only. In this mini-review, we demonstrate the successfully adoption, propagation, and utility of the C. hominis strain TU502, isolated originally from an infant with diarrhea in Uganda, in gnotobiotic piglets. The TU502 C. hominis strain and the gnotobiotic piglet model currently are the only available preclinical tools to evaluate therapeutics that specifically target C. hominis. Infection in this gnotobiotic piglet model displays similar clinical symptoms of diarrhea observed in humans. Here we further describe how this unique model of acute diarrhea, can be used for drug discovery and testing of vaccine candidates against cryptosporidiosis. The shared anatomical, physiological and immunological characteristics between piglets and human infants makes the model ideal for evaluating the efficacy of therapeutics and vaccines against cryptosporidiosis as they become available.

21 July 2022 in Infection and Immunity
Verified
Journal Article
Open access
DDDenise Ann Dayao
Denise Ann Dayao
JJJustyna Jaskiewcz
Justyna Jaskiewcz
SLSangun Lee
Sangun Lee
BOBruno Cesar Oliveira
Bruno Cesar Oliveira
ASAbhineet Sheoran
Abhineet Sheoran
STSaul Tzipori
Saul Tzipori
Cryptosporidiosis was shown a decade ago to be a major contributor to morbidity and mortality of diarrheal disease in children in low-income countries. A serious obstacle to develop and evaluate immunogens and vaccines to control this disease is the lack of well-characterized immunocompetent rodent models.

18 April 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
MHMatthew A. Hulverson
Matthew A. Hulverson
RCRyan Choi
Ryan Choi
DSDeborah A. Schaefer
Deborah A. Schaefer
DBDana P. Betzer
Dana P. Betzer
MMMolly C. McCloskey
Molly C. McCloskey
WVWesley C. Van Voorhis
Wesley C. Van Voorhis
Recent advances on the development of bumped kinase inhibitors for treatment of cryptosporidiosis have focused on the 5-aminopyrazole-4-carboxamide scaffold, due to analogs that have less hERG inhibition, superior efficacy, and strong in vitro safety profiles. Three compounds, BKI-1770, -1841, and -1708, showed strong efficacy in C. parvum infected mice.